Evaluates regulatory decision impact with approval probability, timeline analysis, and outcome scenario modeling for event-driven positions. Use when analyzing regulatory events, evaluating FDA/FCC/DOJ decisions, or modeling regulatory outcomes.
Scanned 9/12/2026
Install to Claude Code
npx -y skills add CaseMark/skills --skill analyzing-regulatory-event-impacts --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Analyzing Regulatory Event Impacts?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/casemark-analyzing-regulatory-event-impacts)More formats (shields.io, HTML) on the badges page.
---
name: analyzing-regulatory-event-impacts
language: en
description: Evaluates regulatory decision impact with approval probability, timeline analysis, and outcome scenario modeling for event-driven positions. Use when analyzing regulatory events, evaluating FDA/FCC/DOJ decisions, or modeling regulatory outcomes.
tags:
- analysis
- activist-and-event-driven-investing
- regulatory
metadata:
author: casemark
practice_areas:
- Activist Investing
- Event-Driven Strategy
- Special Situations
document_types:
- Analysis Report
skill_modes:
- Analysis
---
# Analyzing Regulatory Event Impacts
## When To Use
- Sizing or adjusting positions ahead of binary regulatory decisions (FDA PDUFA dates, FCC spectrum auctions, DOJ/FTC merger reviews, EPA rule finalizations)
- Evaluating whether the market is correctly pricing regulatory risk in an event-driven thesis
- Modeling scenario-weighted outcomes for activist campaigns that hinge on regulatory clearance
- Assessing second-order impacts of regulatory decisions on peers, suppliers, or adjacent sectors
## Inputs To Gather
- **Regulatory event identification**: Agency, docket/application number, decision type (approval, denial, conditional approval, consent decree), statutory deadline or expected ruling date
- **Precedent data**: Historical approval rates for the specific agency and decision category (e.g., FDA NDA approval rates by therapeutic area, FTC merger challenge rates by HHI threshold)
- **Company/asset specifics**: Filing details, advisory committee votes, pre-decision communications (RTF letters, second requests, comment periods), management guidance on timing
- **Market positioning data**: Current implied probability from options pricing, spread levels (for merger arb), short interest, analyst consensus
- **Stakeholder map**: Key commissioners/reviewers, political dynamics, lobbying spend, public comment sentiment, Congressional interest or pressure
## Workflow
1. **Classify the regulatory event**
- Identify the agency, decision framework, and statutory/procedural timeline
- Determine if the event is binary (approve/deny) or multi-outcome (approve/conditional/delay/deny)
- Note any accelerated review designations (FDA Breakthrough, Priority Review) or extended review triggers (second requests, Phase II investigations) [VERIFY against current agency procedures]
2. **Estimate base-rate approval probability**
- Pull historical approval/clearance rates for the specific decision category and agency division
- Adjust for case-specific factors: advisory committee recommendation, completeness of filing, prior agency interactions, political environment
- Assign a probability to each outcome branch (e.g., full approval 55%, conditional approval 20%, CRL/delay 15%, denial 10%)
3. **Map the timeline and catalysts**
- Identify the statutory decision deadline (PDUFA date, HSR waiting period expiry, comment period close)
- Assess likelihood and triggers for timeline extensions (additional information requests, litigation risk, consent decree negotiations)
- Flag intermediate catalysts that update probability (advisory committee votes, staff recommendations, intervenor filings)
4. **Model outcome scenarios and price impacts**
- For each outcome branch, estimate the target price or spread movement based on comparable precedent events
- Calculate the expected value: sum of (probability × payoff) across all branches
- Compare the expected value to the current market-implied probability derived from options skew, merger spreads, or CDS levels
- Identify the edge: where your estimated probability materially diverges from the market's implied probability
5. **Assess second-order and contagion effects**
- Determine if the regulatory decision creates precedent affecting peer companies, competing applications, or industry regulation
- Map supply-chain or partnership impacts (e.g., a drug approval affecting a CDMO, a merger block affecting a target's JV partners)
- Evaluate whether the decision shifts the regulatory posture of the agency for future filings in the same category
6. **Synthesize position recommendations**
- Recommend position sizing relative to the edge and the payoff asymmetry
- Specify instrument selection: equity, options structures (risk reversals, straddles for timing uncertainty), CDS, or merger arb spread trades
- Define stop-loss or hedge triggers tied to intermediate catalyst outcomes
- Set the decision review calendar aligned to the regulatory timeline
## Output
Deliver a structured regulatory event impact report containing:
- **Event summary**: Agency, decision type, statutory deadline, current stage of review
- **Probability matrix**: Table of outcomes with assigned probabilities and supporting rationale for each
- **Timeline map**: Key dates, intermediate catalysts, and extension risk factors
- **Scenario P&L table**: Price targets per outcome, expected value calculation, and comparison to market-implied probability
- **Edge assessment**: Quantified divergence between estimated and market-implied probabilities with confidence level
- **Trade recommendation**: Instrument, direction, sizing framework, and risk triggers
- **Peer/sector impact**: Second-order effects on related positions or watchlist names
## Quality Checks
- Verify that outcome probabilities sum to 100% and that no branch is omitted
- Confirm the base-rate data source and date — historical approval rates shift over time [VERIFY that precedent data reflects the current regulatory administration's posture]
- Cross-check the market-implied probability calculation (e.g., options-implied move vs. spread-implied probability) against at least two independent data sources
- Ensure timeline assumptions account for agency-specific procedural rules and recent track record on meeting deadlines [VERIFY statutory deadlines against current agency guidance]
- Flag any political or personnel changes at the agency (new commissioner, acting leadership, pending nominations) that could alter decision dynamics
- Confirm that position sizing recommendations respect portfolio-level risk limits and liquidity constraints for the instruments recommended
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!